About 50 years ago, an outbreak of *M. pneumoniae* in a pediatric chronic care facility was described (Baernstein et al., [@B1]). Twenty years earlier, the organism had been identified by Eaton and since the early 1960s, it was clearly identified as a bacterium which was associated both in children and adults with community-acquired infections of the respiratory tract (Lambert, [@B24]). Since then, numerous reports have been published on the association of *M. pneumoniae* with community-acquired infections (Waites and Talkington, [@B48]). Given the wide variations of data from studies with equally wide variation of and lack of standardized diagnostic methods, the true role of *M. pneumoniae* in RTIs still remains a challenge.

Since its discovery, scientists have explored several strategies for an optimal diagnosis of a *M. pneumoniae* infection in the laboratory to initiate an appropriate treatment. Because of its fastidious nature, *M. pneumoniae* is not routinely cultured from respiratory specimens. Culture methods have been the gold standard for diagnosis but are too insensitive producing a result after several days or even several weeks and are therefore not relevant for the management of acute illness. Alternative diagnostic procedures were developed: Detection of IgM and/or IgG by ELISA, antigen detection by immunochromatography, and nucleic acid amplification techniques (NAATs), mainly PCR, although also isothermal amplification techniques such as LAMP (loop-mediated isothermal amplification method) have been developed. The utility of culture for *M. pneumoniae* was assessed by comparing it to PCR and IgM serology in a large study (She et al., [@B42]). Given the extremely low yield of culture and the wide availability of NAAT and serology, the authors concluded that culture for *M. pneumoniae* should be discontinued. Nowadays, most studies are serology and/or PCR-based. Different clinical specimens can be used as described in the review by Loens et al. ([@B30]) for the latter.

Application of NAATs {#s1}
====================

PCR is accepted as a rapid diagnostic test. Few of the currently available NAATs have been extensively validated against culture. The sensitivity of NAATs is almost always superior to that of traditional procedures and they are more and more considered as the "new gold standard."

An increasing body of literature describing the use of in-house NAATs for detection of *M. pneumoniae* DNA or RNA in various diseases is available with a great variation of methods used from study to study, including variability of target (P1 adhesin gene, 16S rRNA, ATPase gene, protease gene, CARDS toxin gene), NAAT (conventional, nested, real-time; monoplex vs. multiplex; PCR vs. isothermal amplification technologies), detection formats, and different platforms. An overview of the literature on the use of NAATs to detect *M. pneumoniae* since 1989 is given in two reviews (Loens et al., [@B29], [@B27]).

Lately, efforts have been mainly emphasized on the development of multiplex assays (Nummi et al., [@B36]; Shen et al., [@B43]) and on the evaluation of commercially available assays. Respiratory viruses and other so called "atypical bacteria" are all responsible for RTIs that may produce clinically similar manifestations. In order to reduce costs and hands-on-time, multiplex NAATs for the simultaneous detection of 2, 3, or up to more than 20 different respiratory pathogens in one tube with a mixture of primers have been developed by some groups. However, comparison between mono-and multiplex assays has been rarely performed. Findings and conclusions result frequently in contradictory and conflicting data concerning the sensitivity and specificity of the multiplex NAATs compared to the mono NAATs. This is not unexpected since the presence of several pairs of primers may increase the probability of mispairing resulting in non-specific amplification products and the formation of primer-dimers. Furthermore, enzymes, primers, and salt concentrations as well as temperature cyclings required for each target may be slightly different. The results of the proficiency panels (Loens et al., [@B28], [@B31]) described previously seem to confirm that multiplex assays are somewhat less sensitive than monoplex assays but until the number of organisms present in clinical specimens of diseased individuals is known, it is impossible to state whether the degree of sensitivity attained is clinically acceptable.

Since the previous review (Ieven and Loens, [@B18]) new NAATs became commercially available such as the Illumigene (Meridian Bioscience, USA) kit. It has been proposed that industry-produced assays in kit form result in better standardization. The analytical sensitivity of the Illumigene assay was evaluated by using 36 frozen stock cultures of *M. pneumoniae* reference strains, and a collection of other microorganisms and human DNA. (Ratliff et al., [@B40]). Serial dilutions of cultures with a known CFU/ml defined the analytical sensitivity at ≤88 CFU/ml. Based on the results obtained with 214 archived respiratory specimens, previously cultured for *M. pneumoniae*, the clinical sensitivity and specificity were found to be 100 and 99%, respectively, after resolving discrepancies by PCR and sequencing.

A second example of a test approved for the detection of a number of respiratory viruses by the US Food and Drug Administration is the Filmarray Respiratory panel (bioMérieux, France). The Filmarray is a small desktop closed single-piece flow real-time PCR system. It includes automation of nucleic acid extraction, an initial reverse transcription and multiplex PCR, followed by singleplex second stage PCR reactions for the detection of 15 viral agents including adenovirus, coronavirus HKU1, coronavirus NL63, human metapneumovirus, rhinovirus/enterovirus, influenza A/B, influenza A H1, AH1 2009, A H3, parainfluenza 1--4, and respiratory syncytial virus (Poritz et al., [@B38]). In May 2012, the US Food and Drug Administration expanded the use for the Filmarray respiratory panel with the addition of *B. pertussis, M. pneumonia*, and *C. pneumoniae*. The expanded panel detects now a total of 17 viruses and three bacteria. The test requires 5 min hands-on-time and 65 min instrumentation time. In 2013, a new version of the Filmarray (version 1.7) was released (Doern et al., [@B7]).

The Argene Respiratory MWSr-gene concept allows the detection of numerous pathogens (Influenza A/B, respiratory syncytial virus/human metapneumovirus, rhinovirus/enterovirus, adenovirus/bocavirus, *Chlamydia/Mycoplasma pneumoniae*, human coronavirus/parainfluenza virus, *Bordetella, Bordetella parapertussis*) in the same run. In addition, the diagnostic strategy can be adapted to the season: searching for the most likely pathogens can be considered in 1st stage, the remaining pathogens being searched for systematically in a 2nd stage.

Pillet et al. ([@B37]) compared six commercially available multiplex assays for the diagnosis of respiratory pathogens. Two out of six were also capable of detecting *M. pneumoniae*: the RespiFinder SMART 22 (PathoFinder, The Netherlands) and the Seeplex RV15 OneStep ACE detection and Pneumobacter ACE detection (Seegene Inc, South Korea). Sensitivities and specificities were calculated against the ArgeneChla/Myco pneumo assay (bioMérieux, France). Sensitivity and specificity were 70.0 and 100%, respectively, for the RespiFinder assay and 80.0 and 98.73% for the Seegene assay.

Dumke et al. compared four commercially available real-time PCR assays recommended for use with the Roche LightCycler 1.5 and 2.0 instruments \[Diagenode *Mycoplasma/Chlamydophila pneumoniae* real-time PCR (Diagenode, Belgium), GeneProof *M. pneumoniae* (GeneProof, Czech Republic), BactoReal *M. pneumoniae* (Ingenetix, Austria), LightMix kit *M. pneumoniae* (TIB MOLBIOL, Germany)\] for the detection of *M. pneumoniae* to results obtained with an in-house approach (Dumke and Jacobs, [@B8]) by using serial dilutions of a cultured *M. pneumoniae* strain tested in eight parallel runs and 37 clinical specimens, previously found to be *M. pneumoniae* positive by the in-house assay. All NAATs detected 20 colony forming units (CFU)/5μl sample. Only the in-house-test (repMP1-based approach) was able to detect 0.2 CFU/5μl sample. 37/37,35/37, 35/37, 34/37 *M. pneumoniae* positive clinical specimens were confirmed by the Diagenode test, the Ingenetix and Lightmix assay, and the GeneProof assay respectively.

An overview of commercially available NAATS for the detection of *M. pneumoniae* is presented in Table [1](#T1){ref-type="table"}.

###### 

**Summary of commercially available single and multiplex PCR assays for detection of *M. pneumonia***.

  **Kit**                                                             **Manufacturer**         **Assay type**   **Detection procedure**                      **Pathogens targeted**
  ------------------------------------------------------------------- ------------------------ ---------------- -------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *M. pneumoniae* BDProbeTec ET                                       BD                       SDA              Fluorescence                                 *M. pneumoniae*
  ASR MPN                                                             Cepheid                  PCR              Real-time                                    *M. pneumoniae*
  Simplex *M. pneumoniae*                                             Focus diagnostics        PCR              Real-time                                    *M. pneumoniae*
  GeneProof *Mycoplasma pneumoniae*                                   GeneProof                PCR              Real-time                                    *M. pneumoniae*
  Loopamp *Mycoplasma pneumoniae* DNA amplification kit               Eiken chemical           LAMP             Turbidity                                    *M. pneumoniae*
  BactoReal *Mycoplasma pneumoniae*                                   Ingenetix                PCR              Real-time                                    *M. pneumoniae*
  **Illumigene *Mycoplasma***                                         Meridian BioScience      LAMP             Turbidity                                    *M. pneumoniae*
  Venor MP                                                            Minerva BioLabs          PCR              Agarosegel electrophoresis and real-time     *M. pneumoniae*
  *M. pneumoniae* LightMix kit                                        TIB MolBIOL              PCR              Real-time                                    *M. pneumoniae*
  Cp/Mp tracer                                                        Affigene                 MX-PCR           Real-time                                    *M. pneumoniae, C. pneumoniae*
  AID CAP bacterial assay                                             AID GmbH                 MX-PCR           ICT                                          *S. pneumoniae, H. influenzae, M. catarrhalis, C. pneumoniae, M. pneumoniae, L. pneumophila*
  Chlamylege                                                          Argene, bioMérieux       MX-PCR           Hybridization                                *C. pneumoniae, M. pneumoniae, Legionella spp*
  EasyPlex respiratory pathogens B and C                              Ausdiagnostics           MX-PCR           Real-time                                    Influenza A, influenza A H1, influenza A H3, influenza A H5, influenza B, RSV, rhinovirus, enterovirus, PIV 1-3, HAdV, hMPV, HCoV 229E and OC43, *B. pertussis, M. pneumoniae, C. pneumoniae, L. pneumophila, L. longbeachae, Pneumocystis, H. influenzae, S. pneumoniae*
  Respiratory Multi Well System Chla/Myco pneumo r-gene               BioMérieux               5 duplex PCRs    Real-time                                    Influenza A, influenza B, RSV, hBoV, HAdV, hMPV, rhino/enterovirus, *C. pneumoniae, M. pneumoniae*
  Diagenode *Mycoplasma/Chlamydophila pneumoniae* real-time PCR kit   Diagenode                Duplex PCR       Real-time                                    *M. pneumoniae, C. pneumophila*
  Fast Track Respiratory Pathogen assay                               Fast-track diagnostics   MX-PCR           Real-time                                    *S. pneumoniae, S. aureus, H. influenzae, M. catarrhalis, Legionella spp, M. pneumoniae, C. pneumoniae*
  ProPneumo-1                                                         Hologic                  MX-PCR           Real-time                                    *M. pneumoniae, C. pneumoniae*
  ProPneumo1+                                                         Hologic                  MX-PCR           Real-time                                    *M. pneumoniae, C. pneumoniae*
  **Filmarray**                                                       BioMérieux.              MX-PCR           Microarray                                   Influenza A H1N1, influenza A H1, influenza A H3, influenza B, RSV, hMPV, HCoV NL63, OC43, 229E, HKU1, HAdV PIV 1-4, HBoV, rhino/enterovirus, *B. pertussis, M. pneumoniae, C. pneumoniae*
  RespiFinder plus                                                    Patho Finder             MX-PCR           Capillary electrophoresis                    *M. pneumoniae, C. pneumoniae, L. pneumophila, B. pertussis*, Influenza A (H5, non-specific) and B, RSV A/B, PIV 1-4, rhinovirus, 3 HCoV, hMPV, HAdV
  RespiFinder focus                                                   Patho Finder             MX-PCR           Capillary electrophoresis or microfluidics   *M. pneumoniae, C. pneumoniae, L. pneumophila, B. pertussis*, influenza A and B, RSV A/B, hMPV, HAdV
  SmartFinder                                                         Patho Finder             MX-PCR           Real-time                                    *M. pneumoniae, C. pneumoniae, L. pneumophila, B. pertussis*, influenza A and B, RSV A/B, PIV 1-4, HAdV, rhinovirus, 3 HCoV, hMPV, HBoV
  Seeplex PneumoBacter ACE                                            Seegene Inc.             MX-PCR           Capillary electrophoresis                    *S. pneumoniae, H. influenzae, M. pneumoniae, C. pneumoniae, L. pneumophila, B. pertussis*
  Seeplex RV/PB18 ASE                                                 Seegene Inc.             MX-PCR           Capillary electrophoresis                    *S. pneumoniae, H. influenzae, M. pneumoniae, C. pneumoniae, L. pneumophila*, Influenza A and B, RSV A/B, PIV 1-3, rhinovirus, 3 HCoV, HAdV, HBoV, enterovirus

*Bold, FDA-approved test*.

*HAdV, human adenovirus; HBoV, human bocavirus; HCoV, human coronavirus, hMPV, human metapneumovirus; ICT, immunochromatographic test; LAMP, Loop-Mediated isothermal amplification method; MX-PCR, multiplex PCR; PIV, parainfluenzavirus; qPCR, quantitative PCR*.

Since the calculation of the sensitivities of the commercial multiplex assays was mainly dependent on DNA copy number, further evaluation and standardization using an extended number of clinical specimens that may have a low bacterial load are needed. The use of an international standard developed by the WHO for harmonization of *Mycoplasma* NAAT (Nübling et al., [@B35]) or the yearly participation in the external quality assessment (EQA) panel for *M. pneumoniae* and *Chlamydophila pneumoniae* available from Quality Control for Molecular Diagnostics (QCMD, United Kingdom) should be considered.

So far, it is unclear whether asymptomatic carriage of *M. pneumoniae* in adults and children exists and if colonization could be differentiated from infection by the current diagnostic methods. There are only few data on the relation between the bacterial load and the severity of infection. 405 asymptomatic children and 321 children with a RTI were enrolled in a cross-sectional study (Spuesens et al., [@B45]). Nasopharyngeal washings and pharyngeal swabs were investigated by culture and quantitative real-time PCR (qPCR). Serum was collected for IgM and IgG ELISA. Neither qPCR, serology nor culture was capable of differentiating colonization from infection. In 21.2 and 16.2% of the asymptomatic and symptomatic children, *M. pneumoniae* DNA was detected. In addition, persistence of *M. pneumoniae* in the upper respiratory tract was shown for up to 4 months by longitudinal sampling. A retrospective study investigated the clinical significance of the *M. pneumoniae* bacterial load in children with a *M. pneumoniae* pneumonia (Jiang et al., [@B22]). The authors concluded that a high bacterial load was indicative for a *M. pneumoniae* infection, whereas for a low bacterial load the etiologic role of *M. pneumoniae* remains to be determined.

Edin et al. developed a qPCR with duplex reactions targeting eight bacteria, including *M. pneumoniae*, and six viruses (Edin et al., [@B11]). Clinical specimens from the upper and lower respiratory tract were used to compare the qPCR assay with standard microbiological methods. The use of the qPCR assay resulted in 113 positive identifications in 94 respiratory specimens compared with 38 by using standard diagnostics. The authors conclude that in parallel qPCR detection of the targeted respiratory bacteria and viruses is feasible since a good technical performance of the assay in clinical specimens was obtained.

In contrast to the above mentioned studies, Jain et al. ([@B20]) examined specimens from 2222 hospitalized children with community-acquired pneumonia and 521 asymptomatic controls for the detection of a variety of respiratory pathogens. *M. pneumoniae* was detected in 8%, and in 3% or less of controls.

Another trend is the simultaneous detection of *M. pneumoniae* and mutations associated with macrolide resistance directly in clinical specimens (Ji et al., [@B21]; Liu et al., [@B26]; Nummi et al., [@B36]; Zhao et al., [@B52]).

Application of serology for the detection of *M. pneumoniae* infections {#s2}
=======================================================================

Serological methods, in particular enzyme-linked immunosorbent assays (ELISA), are most widely used to diagnose a *M. pneumoniae* infection. The complement fixation test (CFT) has been replaced by assays which allow for quantification of IgM, IgA, or IgG. However, the most convincing evidence of an ongoing infection is a significant increase in IgG or an IgG seroconversion in paired sera, collected 3--4 weeks apart (Nir-Paz et al., [@B34]). Although IgM antibodies appear earlier than IgG antibodies, and are thus an attractive alternative for diagnosis of a *M. pneumoniae* infection, one should realize that IgM is not often produced in very young children, in a proportion of primary infections and during re-infections (Waites et al., [@B47]; Loens et al., [@B27]).

Ten serological assays for the diagnosis of a *M. pneumoniae* infection were recently evaluated by using 145 sera from 120 patients (Busson et al., [@B3]): SeroMP IgM and IgG (Savyon Diagnostics), SeroMP Recombinant IgM, IgA and IgG (Savyon Diagnostics), LIAISON *M. pneumoniae* IgM and IgG (Biotrin International Ltd), *M. pneumoniae* IgM, IgA and IgG Medac (Medac GmbH). A low IgM specificity and cross-reactivity was noticed for the SeroMP recombinant and Liaison assay. For IgA, the Medac assay tended to be less specific than the SeroMP Recombinant assay. All four tests showed discrepancies in the IgG measurements confirming results of previous studies (Talkington et al., [@B46]; Beersma et al., [@B2]). In conclusion, serology remains a diagnostic tool of choice but improvement and standardization of the assays are still needed, especially for the determination of IgG.

The clinical significance of a serologic test, both for IgM and IgG, should be defined by studies of patients with a documented infection and for whom detailed information concerning the time lapses between onset of disease and the collection of the serum specimens are known.

A promising blotting technique improving the performance of the *M. pneumoniae* serological assays has been described (Dumke et al., [@B10]).

Detection of *M. pneumoniae* by both NAATs and serology {#s3}
=======================================================

Data from recent studies using PCR based methods and serology published during the last decade in different patient populations from around the world are summarized in the recent reviews published by Ieven and Loens (Loens et al., [@B27]; Ieven and Loens, [@B18]) and updated in Table [2](#T2){ref-type="table"}.

###### 

**Summary of recent single and multiplex NAATs for detection of *Mycoplasma pneumoniae* published since the previous review, and previously validated assays used as comparators**.

  **Monoplex assays**                                                                                                                                                                                                                                                              
  ------------------------------- ---------------- ---------------------- --------------------------------- -------------------------------------------------------------------------------------------------------------------------------- ------------------------------------- -----------------------------------------------------------------------------------------------
  **Assay year (references)**     **Assay type**   **Detection format**   **Gene target (product size)**    **PCR assay used as comparator for new assay**                                                                                   **Non-PCR comparator test**           **Specimens tested for validation of sensitivity and or specificity**
  2012 (Zhao et al., [@B51])      PCR              Real-time              P1-gene (72)                      repMp1 and Mp181                                                                                                                                                       Various bacterial species, bacterial dilution series, well-defined clinical specimens
  2012 (Gotoh et al., [@B13])     LAMP             Turbidity              P1 operon (NS) (Eiken Chemical)                                                                                                                                    IgG seroconversion/significant rise   Samples from 368 pneumonia patients
  2013 (Chaudhry et al., [@B6])   PCR              Real-time              P1-gene (534)                     Conventional PCR (NS)                                                                                                            IgM, IgG and IgA serology             Dilution series, respiratory samples from CAP-patients,
  2013 (Schmitt et al., [@B41])   PCR              Real-time              ptsI (160)                        LightMix kit *M. pneumoniae* (TIB MOLBIO), *M. pneumoniae* analyte specific reagent (Focus diagnostics), (Dumke et al., [@B9])                                         Bacterial dilution series, spiked clinical specimens, well-defined clinical specimens
  2014 (Liu et al., [@B26])       PCR              Cycleave               23S rDNA (Takara BioInc)          (Ieven et al., [@B19])                                                                                                                                                 Various bacterial species, bacterial dilution series, clinical specimens
  2014 (Ratliff et al., [@B40])   LAMP             Turbidity              Illumigene assay (208)            2nd real-time PCR and sequencing                                                                                                 Culture                               Various bacterial species, bacterial dilution series, 214 culture positive/negative specimens
  2014 (Medjo et al., [@B32])     PCR              Real-time              P1 (125)                                                                                                                                                           IgM and IgG serology, culture         Specimens from CAP-patients

  **Multiplex assays**                                                        
  -------------------------------- ------------ ----------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  2013 (Puppe et al., [@B39])      MX-PCR       ELISA                         Culture supernatans of the organisms, clinical specimens from frozen stocks, prospectively included nasopharyngeal aspirates
                                                                              Pathogens targeted: enterovirus, influenza A, influenza B, RSV, PIV 1-4, HAdV, rhinovirus, hMPV, HCoV, reovirus, *M. pneumoniae, C. pneumoniae, B. pertussis, B. parapertussis, L. pneumophila*
  2013 (Simões et al., [@B44])     MX-PCR       Affimetrix Chip-image file    Clinical specimens simultaneously investigated by culture and two commercially available assays: the Eragen assay and the Luminex RVP
                                                                              Pathogens targeted: 72 pathogens
  2013 (Weinberg et al., [@B49])   MX-PCR       TAC-array                     Well-defined clinical specimens analyzed by individual real-time PCRs
                                                                              Pathogens targeted: HAdV, hMPV, PIV1-4, influenza A, influenza B, influenza C, RSV, rhinovirus, HCoV OC43, 229E, NL63, HKU1, enterovirus, *B. pertussis, C. pneumoniae, H. influenza, L. pneumophila, M. pneumoniae, S. pneumoniae, S. pyogenes*
  2014 (Hirama et al., [@B16])     MX-PCR       Real-time                     DNA dilution series, welldefined clinical specimens from CAP-patients
                                                                              Pathogens targeted: *S. pneumoniae, H. influenza, M. catarrhalis, P. aeruginosa, K. pneumoniae, E. coli, S. aureus, M. pneumoniae, C. pneumoniae, C. psittaci, C. burnetii, Legionella spp, L. pneumophila, B. pertussis, M. tuberculosis, M. intracellulare, M. avium, M. kansasii, P. jeroveci, Nocardia spp*, metallo-beta-lactamase, MRSA
  2014 (Ji et al., [@B21])         MX-PCR       Agarose gel electrophoresis   Various bacterial pathogens, bacterial dilution series, confirmation by sequencing, well-defined clinical specimens
                                                                              Pathogens targeted: *M. pneumoniae* and associated macrolide resistance
  2015 (Zhao et al., [@B52])       Duplex PCR   Real-time                     Pathogens targeted: *M. pneumoniae* and genotyping
  2015 (Shen et al., [@B43])       MX-PCR       Resequencing microarray       Pathogens targeted: *S. pneumoniae, M. pneumoniae, H. influenza, K. pneumoniae, M. catarrhalis, S. aureus, P. aeruginosa, M. tuberculosis, N. meningitidis*, Group A Streptococci
  2015 (Nummi et al., [@B36])      MX-PCR       Real-time                     Pathogens targeted: *M. pneumoniae, C. pneumoniae* and mutations associated with macrolide resistance

HAdV, human adenovirus; HBoV, human bocavirus; HCoV, human coronavirus; hMPV, human metapneumovirus; PIV, parainfluenzavirus; MX-PCR, multiplex PCR; LAMP, Loop-mediated isothermal amplification; TAC, Taqman Array Card.

The availability of the very sensitive NAATs has in recent years also put the often used serological tests in their right perspective and allow a better interpretation of the serological test results and their limitations such as the low sensitivity of IgM antibodies in acute phase specimens and importance of the delay between two serum samples. Studies in which also NAAT\'s are used on respiratory specimens should allow a better interpretation of the serological test results.

A rapid response report from the Canadian Agency for Drugs and Technologies in Health (Canadian Agency for Drugs and Technologies in Health, [@B4]) presents the results of a literature search in order to identify the diagnostic test accuracy, clinical effectiveness, and cost-effectiveness of serum IgM and molecular tests for the detection of *M. pneumoniae* in patients with a respiratory infection[^1^](#fn0001){ref-type="fn"}. Six relevant studies were identified, but no evidence regarding the clinical effectiveness or cost-effectiveness of a serum IgM test compared with molecular tests was identified. Zhang et al. conducted a systematic review and meta-analysis on the diagnosis of *M. pneumoniae* by PCR and serology (Zhang et al., [@B50]) and reported a significant heterogeneity between the studies and inconsistent results as well.

Two studies compared the application of real-time PCR and serology in children with pneumonia. In 2011, 54/290 children were found to be positive by PCR (Chang et al., [@B5]), 44/182 were *M. pneumoniae* IgM positive. 12.6% of patients were found to be *M. pneumoniae* positive by both tests at the same time. Using PCR as gold standard, a sensitivity and specificity of resp. 62.2 and 85.5% were obtained. The specificity could be increased to 90.3% by increasing the cut-off without changing the sensitivity of the IgM assay. A study conducted by Medjo et al. ([@B32]) applied PCR, culture, IgM and IgG in paired sera for the detection of a *M. pneumoniae* infection in 166 children. Using IgG serology as gold standard, the sensitivity of IgM, PCR, and culture was found to be equal (81.8%), specificity was found to be 100, 98.6, and 100% respectively. It was concluded that during the acute phase of disease, detection of IgM antibodies in combination with PCR allowed for a precise and reliable *M. pneumoniae* diagnosis. A prospective study in children with community-acquired CAP (Kakuya et al., [@B23]) compared loop-mediated isothermal amplification, (LAMP), culture and serology at first visit. Patients were defined positive if positive by culture and/or sero-conversion or a four-fold increase in IgG in paired sera. 31/191 patients met the criteria. Thirteen were positive by culture and serology, 17 on culture only, and one by serology only. A positive LAMP result was obtained for all patients that were culture positive. The sensitivity and specificity for LAMP, EIA, and the particle agglutination test, were 96.8, 38.7, 19.4, and 100%, 76.9 and 93.1%, respectively.

When establishing the etiology in 267 adult CAP-patients in Norway, 10 were found to be *M. pneumoniae* positive: two by serology, seven and one by PCR applied to a nasopharyngeal flocked swab and an oropharyngeal flocked swab, respectively (Holter et al., [@B17]).

Amplification-free and other technological developments {#s4}
=======================================================

Newer technologies such as microfluidics and the application of nanotechnology offer the potential to an even more rapid detection of important pathogens allowing even near-patient testing. Since these technologies, as NAATs, do not require viable organisms, and thus avoid any adverse effect of longer specimen transport, they can be successfully applied to both the in- and outpatient settings. Several companies currently possess the technical expertise and research infrastructure to bring a useful diagnostic testing approach to the clinical trial stage shortly.

Li et al. ([@B25]) developed a colloidal gold-based immune-chromatographic assay by using a pair of monoclonal antibodies targeting a region of the P1 gene. When applied to 303 clinical specimens from children suspected with a *M. pneumoniae* infection, the sensitivity and specificity against real-time PCR were 100 and 97.4%. This is in contrast to the results obtained with a commercially available rapid antigen test targeting the ribosomal protein L7/L12 (Ribotest Mycoplasma). Compared to real-time PCR, a sensitivity and specificity of respectively 62.5 and 90.9% were obtained when applied to clinical specimens (Miyashita et al., [@B33]). Based on these results, the authors concluded that treatment decisions should not be taken based on the Ribotest results alone.

Other amplification-free detection methodologies are currently being developed as biosensing detection strategies: A proto-type of an enzyme-free electrochemical genosensor on nanostructured screen-printed gold electrodes (Garcia-Gonzalez et al., [@B12]); A silver nanorod array-surface enhanced Raman Spectroscopy biosensing platform was successfully applied for the detection of *M. pneumoniae* in simulated and clinical throat swabs (Henderson et al., [@B15], [@B14]).

Conclusions {#s5}
===========

With the use of tools such as NAATs a greater understanding of the etiology and epidemiology of *M. pneumoniae* is possible. Taken into account the results obtained in recent studies, there is more evidence that real-time NAATs are superior to other *M. pneumoniae* detection strategies during the early phase of infection. NAATs, however, cannot completely replace serology. In epidemiological studies, serology is certainly more useful than for the management of individual patients with LRTI or even CAP since results are often delayed by the need for paired sera to detect a seroconversion or a significant rise in titer; early in the course of an infection, false-negative results often occur.

In case a specific IgM test is used, serology should not completely be abolished despite the fact that IgM serology shows a moderate sensitivity. Nowadays, a combination of the detection of IgM antibodies and PCR may be the most optimal approach for early diagnosis of a *M. pneumoniae* infection, especially in children.

The implementation of quantitative tests could shed further light on the relation between bacterial load and the seriousness of the disease, produce useful prognostic information and help in the differentiation between colonization and infection. More information could be gathered on the length of the post infection carrier state as well as on the importance of subclinical infections and how prone these are for spreading infection.

It remains important to recognize the urgent need for the adoption of a more unified and consistent diagnostic approach for current and future investigations. Therefore, a common set of recommendations should be developed.
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